Management of Gastroesophageal Reflux Disease (GERD)

Introduction to Combination Therapy

The National Comprehensive Cancer Network (NCCN) guidelines recommend considering the addition of an H2 blocker when a PPI alone is not providing adequate symptom control for patients with GERD 1
The American Gastroenterological Association supports adding H2RAs to PPI therapy for additional symptom control in patients with GERD 2
The combined use of H1 and H2 antagonists is superior to the use of either agent alone, as noted in the ESMO clinical practice guidelines, and this principle extends to the combination of PPIs with H2 blockers for enhanced acid suppression in patients with GERD 3

The recommended schedule for combination therapy is to continue pantoprazole in the morning before breakfast and add an H2 blocker (e.g., ranitidine 150 mg) at bedtime to maximize the effectiveness of both medications 1
Standard H2 blocker doses to consider include ranitidine: 150 mg twice daily, famotidine: 20 mg twice daily, and nizatidine: 150 mg twice daily, as noted in the Journal of Hepatology 4

Assess symptom response after 2 weeks of combination therapy, and if inadequate response, consider increasing PPI to twice daily dosing before further adjustments 1
Consider switching to a different PPI, evaluating for non-GERD causes of symptoms, considering diagnostic testing (endoscopy, pH monitoring) to confirm GERD diagnosis, and assessing for functional disorders that may benefit from neuromodulators or other interventions if the combination of PPI and H2 blocker does not provide adequate relief 1

Some medications, such as dasatinib, may have reduced absorption when taken with PPIs or H2 blockers, as noted in the Journal of the National Comprehensive Cancer Network 5
H2 blockers may develop tolerance after continuous use, so their effectiveness might diminish over time, and consider using them intermittently or primarily for nighttime symptom control 1
Acid suppression may reduce the effectiveness of medications requiring gastric acidity for absorption, such as itraconazole capsules, as noted in Clinical Infectious Diseases 6